Product Information
DAPAGLIFLOZIN 5 MG TABLET is a generic product labeled by Prasco Laboratories, priced at $0.1627 per EA under NDC 66993045630. Its NADAC has been published 129 times since Apr 17, 2024.
FDA first approved this application on Jan 8, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
Prasco LaboratoriesNDC
66993045630
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DAPAGLIFLOZIN PROPANEDIOLApproval Type
Authorized Generic (NDA)
FDA Application
NDA202293FDA Approved
1/8/2014
TE Code
AB
On Market Since
1/3/2024
Pharmacological Classes
Price Statistics
The NADAC for DAPAGLIFLOZIN 5 MG TABLET has been published 129 times since Apr 17, 2024, and over the history we have for it it has declined 98.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1627 per EA |
|---|---|
| All-time high | $11.7436 (Oct 16, 2024) |
| All-time low | $0.1627 (Sep 23, 2026) |
| 52-week high | $11.5971 |
| 52-week low | $0.1627 |
| Median price | $11.4429 |
| Average price | $9.8796 |
| Largest weekly change | -98.4% (Jun 3, 2026) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Prasco Laboratories manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
DAPAGLIFLOZIN market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Sodium-Glucose Cotransporter 2 Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DAPAGLIFLOZIN 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for DAPAGLIFLOZIN 5 MG TABLET, manufactured by Prasco Laboratories, is $0.1627 per EA (NDC 66993045630), effective Sep 30, 2026.
How has the price of DAPAGLIFLOZIN 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for DAPAGLIFLOZIN 5 MG TABLET has declined 98.6%. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for DAPAGLIFLOZIN 5 MG TABLET?
Since Apr 17, 2024, the NADAC for DAPAGLIFLOZIN 5 MG TABLET has ranged from a low of $0.1627 (Sep 23, 2026) to a high of $11.7436 (Oct 16, 2024), with a median of $11.4429 per EA.
Are there cheaper alternatives to DAPAGLIFLOZIN 5 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as DAPAGLIFLOZIN 5 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures DAPAGLIFLOZIN 5 MG TABLET?
DAPAGLIFLOZIN 5 MG TABLET (NDC 66993045630) is labeled by Prasco Laboratories, and CMS classifies it as a generic product.